纤溶酶原激活物抑制因子1(PAI1)检测试剂盒(酶联免疫吸附试验法,小样本)
Mini Samples ELISA Kit for Plasminogen Activator Inhibitor 1 (PAI1)
SERPINE1; PLANH1; Serpin Peptidase Inhibitor Clade E Member 1; Nexin,Plasminogen Activator Inhibitor Type 1 Serpin E1; Endothelial plasminogen activator inhibitor
- 编号MEA532Hu
- 物种Homo sapiens (Human，人) 相同的名称，不同的物种。
- 实验方法双抗夹心
- 反应时长3h
- 检测范围12.5-800pg/mL
- 灵敏度最小可检测剂量小于等于4.9pg/mL.
- 样本类型serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下载 英文说明书 中文说明书
- 规格 48T96T 96T*5 96T*10 96T*100
- 价格 ¥ 2512 ¥ 3588 ¥ 16146 ¥ 30498 ¥ 251160
- 欲了解实际交易价格和更多情况，请与当地经销商联系!
-
产品包装(模拟)
-
产品包装(模拟)
-
实验结果图
-
标准曲线图
-
通过ISO 9001、ISO 13485质量体系认证
特异性
本试剂盒用于检测纤溶酶原激活物抑制因子1(PAI1)检测试剂盒(酶联免疫吸附试验法,小样本)，经检测与其它相似物质无明显交叉反应。
由于受到技术及样本来源的限制，不可能完成对所有相关或相似物质交叉反应检测，因此本试剂盒有可能与未经检测的其它物质有交叉反应。
回收率
分别于定值血清及血浆样本中加入一定量的纤溶酶原激活物抑制因子1(PAI1)检测试剂盒(酶联免疫吸附试验法,小样本)（加标样品），重复测定并计算其均值，回收率为测定值与理论值的比率。
| 样本 | 回收率范围(%) | 平均回收率(%) |
| serum(n=5) | 95-103 | 101 |
| sodium citrate plasma(n=5) | 98-105 | 101 |
精密度
精密度用样品测定值的变异系数CV表示。CV(%) = SD/mean×100
批内差：取同批次试剂盒对低、中、高值定值样本进行定量检测,每份样本连续测定20 次，分别计算不同浓度样本的平均值及SD值。
批间差：选取3个不同批次的试剂盒分别对低、中、高值定值样本进行定量测定，每个样本使用同一试剂盒重复测定8次，分别计算不同浓度样本的平均值及SD值。
批内差： CV<10%
批间差： CV<12%
线性
在定值血清及血浆样本内加入适量的纤溶酶原激活物抑制因子1(PAI1)检测试剂盒(酶联免疫吸附试验法,小样本)，并倍比稀释成1:2，1:4，1:8，1:16的待测样本，线性范围即为稀释后样本中纤溶酶原激活物抑制因子1(PAI1)检测试剂盒(酶联免疫吸附试验法,小样本)含量的测定值与理论值的比率。
| 样本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 85-94% | 94-105% | 80-96% | 96-104% |
| sodium citrate plasma(n=5) | 97-104% | 81-92% | 97-105% | 80-96% |
稳定性
经测定，试剂盒在有效期内按推荐温度保存，其活性降低率小于5%。
为减小外部因素对试剂盒破坏前后检测值的影响，实验室的环境条件需尽量保持一致，尤其是实验室内温度、湿度及温育条件。其次由同一实验员来进行操作可减少人为误差。
实验流程
1. 实验前标准品、试剂及样本的准备；
2. 加样（标准品及样本）25µL，37°C温育1小时；
3. 吸弃，加检测溶液A25µL，37°C孵育1小时；
4. 洗板3次；
5. 加检测溶液B25µL，37°C孵育30分钟；
6. 洗板5次；
7. 加TMB底物25µL，37°C孵育10-20分钟；
8. 加终止液20µL，立即450nm读数。
实验原理
将纤溶酶原激活物抑制因子1(PAI1)检测试剂盒(酶联免疫吸附试验法,小样本)抗体包被于96孔微孔板中，制成固相载体，向微孔中分别加入标准品或标本，其中的纤溶酶原激活物抑制因子1(PAI1)检测试剂盒(酶联免疫吸附试验法,小样本)与连接于固相载体上的抗体结合，然后加入生物素化的纤溶酶原激活物抑制因子1(PAI1)检测试剂盒(酶联免疫吸附试验法,小样本)抗体，将未结合的生物素化抗体洗净后，加入HRP标记的亲和素，再次彻底洗涤后加入TMB底物显色。TMB在过氧化物酶的催化下转化成蓝色，并在酸的作用下转化成最终的黄色。颜色的深浅和样品中的纤溶酶原激活物抑制因子1(PAI1)检测试剂盒(酶联免疫吸附试验法,小样本)呈正相关。用酶标仪在450nm波长下测定吸光度(O.D.值)，计算样品浓度。
相关产品
| 编号 | 适用物种：Homo sapiens (Human，人) | 应用(仅供研究使用，不用于临床诊断！) |
| RPA532Hu02 | 纤溶酶原激活物抑制因子1(PAI1)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| EPA532Hu61 | 纤溶酶原激活物抑制因子1(PAI1)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA532Hu01 | 纤溶酶原激活物抑制因子1(PAI1)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APA532Hu61 | 纤溶酶原激活物抑制因子1(PAI1)活性蛋白 | Cell culture; Activity Assays. |
| PAA532Hu01 | 纤溶酶原激活物抑制因子1(PAI1)多克隆抗体 | WB; IHC; ICC; IP. |
| PAA532Hu02 | 纤溶酶原激活物抑制因子1(PAI1)多克隆抗体 | WB; IHC; ICC; IP. |
| LAA532Hu71 | 纤溶酶原激活物抑制因子1(PAI1)多克隆抗体(生物素标记) | WB; IHC; ICC. |
| LAA532Hu81 | 纤溶酶原激活物抑制因子1(PAI1)多克隆抗体(异硫氰酸荧光素标记) | WB; IHC; ICC; IF. |
| MAA532Hu22 | 纤溶酶原激活物抑制因子1(PAI1)单克隆抗体 | WB; IHC; ICC/IF |
| MAA532Hu24 | 纤溶酶原激活物抑制因子1(PAI1)单克隆抗体 | WB; IHC; ICC; IP. |
| MAA532Hu27 | 纤溶酶原激活物抑制因子1(PAI1)单克隆抗体 | WB; IHC; ICC; IP. |
| MAA532Hu29 | 纤溶酶原激活物抑制因子1(PAI1)单克隆抗体 | WB; IHC; ICC; IP. |
| MAA532Hu25 | 纤溶酶原激活物抑制因子1(PAI1)单克隆抗体 | WB; IHC; ICC; IP. |
| MAA532Hu21 | 纤溶酶原激活物抑制因子1(PAI1)单克隆抗体 | WB; IHC; ICC; IP. |
| MAA532Hu26 | 纤溶酶原激活物抑制因子1(PAI1)单克隆抗体 | WB; IHC; ICC; IP. |
| MAA532Hu23 | 纤溶酶原激活物抑制因子1(PAI1)单克隆抗体 | WB; IHC |
| FAA532Hu04 | 抗纤溶酶原激活物抑制因子1(PAI1)单克隆抗体 | Flow cytometry. |
| FAA532Hu02 | 抗纤溶酶原激活物抑制因子1(PAI1)单克隆抗体 | Flow cytometry. |
| FAA532Hu06 | 抗纤溶酶原激活物抑制因子1(PAI1)单克隆抗体 | Flow cytometry. |
| FAA532Hu08 | 抗纤溶酶原激活物抑制因子1(PAI1)单克隆抗体 | Flow cytometry. |
| LAA532Hu74 | 纤溶酶原激活物抑制因子1(PAI1)单克隆抗体(生物素标记) | WB; IHC; ICC. |
| LAA532Hu76 | 纤溶酶原激活物抑制因子1(PAI1)单克隆抗体(生物素标记) | WB; IHC; ICC. |
| MEA532Hu | 纤溶酶原激活物抑制因子1(PAI1)检测试剂盒(酶联免疫吸附试验法,小样本) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| SEA532Hu | 纤溶酶原激活物抑制因子1(PAI1)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| SCA532Hu | 纤溶酶原激活物抑制因子1(PAI1)检测试剂盒(化学发光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| LMA532Hu | 纤溶酶原激活物抑制因子1(PAI1)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
| PSA532Hu01 | 纤溶酶原激活物抑制因子1(PAI1)抗体对 | ELISA; CLIA; ELISPOT; Luminex; Immunochromatography and other Immunoassays. |
| KSA532Hu01 | 纤溶酶原激活物抑制因子1(PAI1)检测试剂盒DIY材料(酶联免疫吸附试验法) | Main materials for "Do It (ELISA Kit) Yourself". |
参考文献
| 杂志 | 参考文献 |
| Breast Cancer Research and Treatment | Oral administration of benzyl-isothiocyanate inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice [SpringerLink: f3w831267267p277] |
| Clin Appl Thromb Hemost. | Is There Any Association Between Thrombosis and Tissue Factor Pathway Inhibitor Levels in Patients With Vitamin D Deficiency? [Pubmed: 24203351] |
| Molecular Nutrition & Food Research | Trans‐fatty acid promotes thrombus formation in mice by aggravating antithrombogenic endothelial functions via Toll‐like receptors [PubMed: 25546502] |
| Archives of Physiology and Biochemistry | Activation of cardiac renin–angiotensin system and plasminogen activator inhibitor-1 gene expressions in oral contraceptive-induced cardiometabolic disorder [Pubmed:26934364] |
| Naunyn-Schmiedeberg's Archives of Pharmacology | Combined oral contraceptive-induced hypertension is accompanied by endothelial dysfunction and upregulated intrarenal angiotensin II type 1 receptor gene expression [pubmed:27447455] |
| Environmental toxicology and pharmacology | Combined oral contraceptive and nitric oxide synthesis inhibition synergistically causes cardiac hypertrophy and exacerbates insulin resistance in female rats. [pubmed:28376377] |
| Annals of Clinical & Laboratory Science | Alteration of Hemostatic Parameters in Patients with Different Levels of Subclinical Hypothyroidism and the Effect of L-thyroxine Treatment [pubmed:28249913] |
| Pharmacological reports | Anti-inflammatory and antithrombotic effects of nicotine exposure in oral contraceptive-induced insulin resistance are glucocorticoid-independent [pubmed:28349880] |
| Haematologica | Cytoprotective and pro-angiogenic functions of thrombomodulin are preserved in the C loop of the fifth epidermal growth factor-like domain [Pubmed:29903766] |
| Biomedicine & Pharmacotherapy | Puerarin prevents vascular endothelial injury through suppression of NF-κB activation in LPS-challenged human umbilical vein endothelial cells [Pubmed:29775893] |
| Archives of Physical Medicine and Rehabilitation | Impact of Regular Physical Activity on Adipocytokines and Cardiovascular Characteristics in Spinal Cord–Injured Subjects [Pubmed:29548578] |
| Marine Drugs | Anticoagulant and Antithrombotic Properties in Vitro and in Vivo of a Novel Sulfated Polysaccharide from Marine Green Alga Monostroma nitidum [Pubmed: 31027312] |
| Experimental and Therapeutic Medicine | IKKβ regulates the expression of coagulation and fibrinolysis factors through the NF‑κB canonical pathway in LPS‑stimulated alveolar epithelial cells type II [Pubmed: 31572531] |
| Phytomedicine | Sodium aescinate significantly suppress postoperative peritoneal adhesion by inhibiting the RhoA/ROCK signaling pathway [Pubmed: 32120245] |
| Sci Rep | Fibroblast growth factor-21 as a novel metabolic factor for regulating thrombotic homeostasis [Pubmed:35013379] |
| Phytomedicine | Multi-omics analysis reveals the mechanisms of action and therapeutic regimens of traditional Chinese medicine, Bufei Jianpi granules: Implication for COPD drug … [Pubmed:35121390] |
